The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004).
Masanori Toyoda
No relevant relationships to disclose
Tetsuo Ajiki
No relevant relationships to disclose
Yutaka Fujiwara
No relevant relationships to disclose
Hiroaki Nagano
No relevant relationships to disclose
Shogo Kobayashi
No relevant relationships to disclose
Daisuke Sakai
No relevant relationships to disclose
Etsuro Hatano
No relevant relationships to disclose
Masashi Kanai
No relevant relationships to disclose
Shoji Nakamori
No relevant relationships to disclose
Atsushi Miyamoto
No relevant relationships to disclose
Akihito Tsuji
Other Remuneration - Taiho Pharmaceutical
Satoshi Kaihara
No relevant relationships to disclose
Hisashi Ikoma
No relevant relationships to disclose
Shigekazu Takemura
No relevant relationships to disclose
Hideyoshi Toyokawa
No relevant relationships to disclose
Hiroaki Terajima
No relevant relationships to disclose
Tatsuya Ioka
Research Funding - Yakult Honsha